AYTU BioPharma, Inc. logo

AYTU BioPharma, Inc. (AYTU) Q1 2026 Earnings

AYTU·Reported May 13, 2026·After market close

AYTU BioPharma, Inc. reported Q1 2026 revenue of $12.4M (-32.7% YoY), beat analyst consensus of $12.1M by $358.3K. Diluted EPS came in at $-0.53, missed the $-0.31 consensus by $0.22.

Revenue
$12.4Mbeat by $358.3K
Consensus: $12.1M
Diluted EPS
$-0.53missed by $0.22
Consensus: $-0.31
SEC

SEC Filings

Earnings release8-K · 0001437749-26-016717
Quarterly report10-Q · 0001437749-26-016721

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about AYTU BioPharma, Inc.'s Q1 2026 earnings report.

AYTU BioPharma, Inc. (AYTU) reported Q1 2026 earnings on May 13, 2026 after market close.

AYTU BioPharma, Inc. reported revenue of $12.4M and diluted EPS of $-0.53 for Q1 2026.

Revenue beat the consensus estimate of $12.1M by $358.3K. EPS missed the consensus estimate of $-0.31 by $0.22.

Compared to the same quarter a year prior, revenue declined 32.7% from $18.5M a year earlier.

You can read the 8-K earnings release (0001437749-26-016717) and the 10-Q periodic report (0001437749-26-016721) directly on SEC EDGAR. The filing index links above go to sec.gov.